Organization
Debiopharm
12 clinical trials
4 abstracts
Clinical trial
A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3Status: Terminated, Estimated PCD: 2020-12-31
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to StaphylococcusStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor ActivityStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 TreatmentStatus: Completed, Estimated PCD: 2022-04-06
Abstract
Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.Org: Merck Serono Ltd., Merck, The Healthcare Business of Merck KGaA, Debiopharm, Institut Gustave Roussy,
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2021-01-13
Clinical trial
A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide FormulationStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Locally Advanced/Metastatic Prostate CancerStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaStatus: Recruiting, Estimated PCD: 2028-09-01
Clinical trial
An Open-Label, Single-Arm, Multi-Center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants Who Are Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious PubertyStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 1 Study of Oral Debio 0123 in Combination With Carboplatin in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-05
Abstract
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.Org: Leiden University Medical Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, University Medical Center Groningen, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Vall d'Hebron Institute of Oncology,
Abstract
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.Org: Memorial Sloan Kettering Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, St Vincent’s Hospital, CHRU de Nancy - Hopitaux de Brabois, Jean Perrin Cancer Center,
Abstract
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).Org: EMD Serono Research & Development Institute, Debiopharm, Merck,